FDA clears GSK lung cancer drug for advanced cases
The FDA granted accelerated approval Tuesday to a GSK drug for patients with an advanced form of lung cancer, Reuters reported. The clearance targets patients whose disease progressed after earlier treatments, a group with limited options left.
- 4 sources report it: yahoo.com, msn.com, oncnursingnews.com, breakingthenews.net.
- The source published it on Nov 17, 2026 at 9:38 AM.
Nothing open. Every check passed.
The US Food and Drug Administration handed GSK's lung cancer drug an accelerated approval on Tuesday, Reuters reported. The green light covers patients with an advanced form of the disease, not the general lung cancer population.
The approval is aimed at patients whose disease has already progressed after earlier treatments — a group with few remaining options. GSK, formally GlaxoSmithKline, now has a cleared path to market the therapy in that setting.
The company has not yet disclosed pricing or a rollout date. Reuters' report was filed from Bengaluru by Kamal Choudhury, with Shailesh Kuber editing.
TopicsGSK · FDA · GlaxoSmithKline
Written by AI from verified reporting.
More stories
- Health & science curetoday.com 0 viewsFDA Fast-Tracks Nelkarmi for Lung Cancers That Outsmarted Earlier Drugs
- Health & science techtimes.com 0 viewsPierre Fabre's lung cancer pill wins FDA fast track with no data public
- Health & science apnews.com 0 viewsUS and Mexico stripped of measles-free status, international health officials say
- Health & science cbsnews.com 0 viewsChina fires scientist after girl, 6, died in hidden gene-editing trial

